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1. Introduction 
1.1 The ocular surface – anatomy and pathology 
The corneal epithelium, conjunctival epithelium, and the lacrimal system constitute the 
ocular surface. A healthy corneal epithelium is essential for corneal health and visual 
function. The corneal epithelium is a 5- to 6-cell-thick layer that provides a defensive barrier 
against pathologic organisms. It exists in a dynamic equilibrium, with superficial cells being 
constantly shed into the tear film. Populations of pluripotent stem cells reside in the 
palisades of Vogt at the human corneoscleral limbus and generate transient amplified cells 
that centripetally migrate toward the central cornea. These transient amplified cells undergo 
terminal differentiation into epithelial cells and repopulate the corneal epithelium, i.e. the 
XYZ hypothesis (Thoft et al., 1983). Severe ocular surface disorders, such as infection, 
keratoconjunctivitis sicca, Stevens-Johnson syndrome, ocular cicatricial pemphigoid or 
chemical/thermal injuries, can progress to corneal scarring, conjunctivalization, 
neovascularization, or stromal melts. Depletion of the limbal stem cells may follow, 
resulting in impaired vision or eventual corneal blindness. According to the World Health 
Organization, corneal disorders, e.g. trachoma or onchocerciasis, constitute a significant 
cause of loss of vision and blindness in the world (Thylefors et al., 1995). 
The conjunctiva is a thin, transparent, mucus membrane, overlying a thin vascular stroma. It 
is divided into three geographic zones: bulbar, forniceal, and palpebral. The conjunctival 
nonkeratinized stratified epithelium contains mucin-producing goblet cells, which are 
important for tear film stability. Additionally, the conjunctiva participates in the ocular 
surface antimicrobial defense via the conjunctiva-associated lymphoid tissue, as well as 
secretory antimicrobial peptides, such as defensins (Haynes et al., 1999). Disorders of the 
conjunctiva include elastotic changes, fibrovascular proliferation, malignancies, and 
autoimmune conditions such as Stevens-Johnson syndrome or cicatricial pemphigoid. 
Complications include dysfunctional tear syndrome, keratinization, symblepharon 
formation, eyelid disfigurement, and eyelash misalignment. Patient discomfort, cosmetic 
imperfection, increased risk of infection, and visual impairment are some notable concerns. 
A normal tear film is essential for maintenance of the corneal and conjunctival epithelia. 
Composed of three layers, mucin, aqueous and lipid layers, the human tripartite tear film 
has antimicrobial, epitheliotrophic, mechanical, and optical properties. A wide range of 
physiologic or pathologic conditions, such as biologic aging, hormonal changes, chemical or 
thermal injuries, chronic inflammation, or autoimmune disorders, may disrupt the tear film 
and trigger a deleterious cascade, injuring ocular surface epithelia. Furthermore, suboptimal 
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lacrimal functions may result in poor surgical outcomes, especially after penetrating 
keratoplasty or limbal stem cell transplantation. 
Traditionally, the eyelids and lacrimal gland were excluded from the definition of the ocular 
surface. It is evident that visual function and epithelial health would not be feasible without 
these structures. The eyelids are essential for ocular surface protection and tear film 
maintenance. Untreated eyelid deformities, lid malpositions, or eyelash misalignments can 
precipitate detrimental consequences to the integrity and function of the ocular surface 
epithelia. Thus, a functional ocular surface requires structurally and functionally intact 
eyelids and lacrimal gland. 
2. Ocular surface reconstitution 
In severe ocular surface disorders, the management strategies entail symptomatic relief, 
reconstitution of the anatomic and physiologic ocular surface, and treatment and prevention 
of recurrence of the causative condition. Here we will discuss strategies to restore the 
conjunctival epithelium, corneal epithelium, and lacrimal function. Figure 1 illustrates the 
management strategies. Injury or inflammation causes severe ocular surface disorder with 
conjunctival scarring, limbal stem cell deficiency, corneal opacity with neovascularization, 
lacrimal dysfunction, disorganized lashes, and lid malposition (a). Mainstay treatment 
options include antibiotics, anti-inflammatory agents, lubrication, and amniotic membrane 
transplantation, as well as removal of lashes and correction of lid changes (b). As progress is 
made in science and tissue bioengineering, tissue replacement and regeneration may be 
feasible to restore the ocular surface and vision (c). 
2.1 Conjunctival tissue reconstitution 
2.1.1 Suppression of cicatricial changes 
Commonly, ocular surface diseases limited to the conjunctiva progress to excessive 
cicatricial changes and loss of normal epithelial anatomy. Cicatricial changes to the 
conjunctival epithelium generally result from poorly controlled fibroblastic activities, e.g. 
tissue injuries or persistent inflammation. In addition to disrupting the tear film, 
cicatricialization of the conjunctiva has important implications in glaucoma surgeries, where 
availablility of healthy conjunctiva is essential for good surgical outcomes. A widely 
adopted therapeutic strategy is pharmacologic suppression of the inflammatory cascade and 
the fibroblast activation pathway using corticosteroids and antimetabolites.  
Recently, research efforts have been directed toward transforming growth factor beta (TGF-
ǃ) and its involvement in fibroblast proliferation. TGF-ǃ is a multifunctional cytokine, which 
plays an important role in tissue repair and regeneration. After injury, TGF-ǃ triggers a 
complex cascade involving monocyte and leukocyte chemotaxis, induction of angiogenesis, 
control of production of cytokines and inflammatory mediators, deposition of extracellular 
matrix materials, and prevention of their enzymatic degradation (Border & Ruoslahti, 1992; 
Massagué et al., 1992). Excessive TGF-ǃ activity has been associated with exuberant fibrotic 
changes in the eye and other organs. In a murine model, TGF-ǃ was associated with 
formation of granulation tissue (Roberts et al., 1986) and increased inflammatory cell 
activity, as well as with exuberant extracellular collagen type-III deposition (Siriwardena et 
al., 1999). Using immunohistochemistry, Razzaque et al (2003) found increased 
accumulations of type-I and type III collagens and heat shock protein 47, a collagen-binding 
protein in fibrotic conjunctiva of patients with ocular cicatricial pemphigoid compared to 
normal subjects. Up-regulation of these proteins was also detected when ex-vivo 
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Fig. 1. Ocular Surface Reconstitution: (a) ocular surface destruction, (b) preliminary 
management – antibiotics; anti-inflammatory; amniotic membrane; eradication of 
microtrauma sources; etc. (c) ocular surface reconstitution – tissue transplant ± 
bioengineered substratum (I); lacrimal gland function restoration (II); corneal transplant or 
keratoprosthesis (III); regenerative medicine, targeted drug delivery, (IV); oculoplastic 
reconstruction, etc. (Adapted from Nguyen et al., 2008) 
conjunctival fibroblasts were treated with TGF-ǃ. Elevated levels of bone morphogenetic 
protein-6 and activin A, both part of the TGF- ǃ superfamily, have been reported in scar 
tissue after glaucoma incisional surgeries, and their mRNA expression was 
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immunolocalized to epithelial cells, vascular endothelia, stromal fibroblasts, and 
macrophage-like cells using real-time polymerase chain reaction (Andreev et al., 2006). It is 
suggested that these multifunctional growth factors participate in tissue wound healing, and 
altered expression of these factors may play a role in conjunctival scarring.  
It is, therefore, hypothesized that modulation of TGF-ǃ activity may help control the 
formation of scar tissue. Indeed, this has been demonstrated in animal models and clinical 
trials. CAT-152 is a human monoclonal antibody capable of neutralizing the growth factor 
TGF-ǃ2. In in vitro and in vivo models, CAT-152 was shown to inhibit conjunctival scarring 
(Cordeiro et al., 1999; Thompson et al., 1999). In a rabbit model, SB-431542, a potent and 
selective inhibitor of the TGF-ǃ1 activin receptor-like kinase, decreases subconjunctival 
deposition of collagen in rabbits undergoing glaucoma filtration surgery (Xiao et al., 2009). It 
is thought that SB-431542 inhibits phosphorylation of Smad2 stimulated by TGF-ǃ, 
abrogating fibroblast transdifferentiation and type-I collagen synthesis. A prospective 
randomized placebo controlled clinical study of patients undergoing trabeculectomy 
showed that subconjunctival injection of CAT-152 appears to be safe in human undergoing 
trabeculectomy (Cordeiro 2003; Siriwardena et al., 2002). Successful and safe suppression of 
TGF- ǃ superfamily activities may modulate fibroblast proliferation and cicatricial changes 
to the conjunctiva. 
An alternative approach is stimulation of tissue regrowth and reduction of the conjunctival 
wound contraction mediated by modified contractile fibroblasts using biocompatible porous 
matrices (Gabbiani et al., 1971; Majno et al 1971). In a guinea pig skin model, highly porous, 
cross-linked collagen-glycosaminoglycan copolymer matrix had been reported to induce 
partial morphogenesis of skin when seeded with dermal and epidermal cells. After grafting 
on a full-thickness skin wound model (Yannas et al., 1982, 1989), the seeded matrix 
regenerated mature epidermis and near physiologic dermis, which was distinct from scar 
tissue and able to prevent wound contraction, compared to non-seeded matrix. For 
ophthalmic applications, porous collagen-glycosaminoglycan copolymer matrix was shown 
to decrease wound contraction in a full-thickness defect in a rabbit conjunctival model (Hsu 
et al., 2000). In animal glaucoma filtration surgery model, implantation of biodegradable 
porous collagen matrix in the subconjunctival space was associated with less initial scar 
formation and maintenance of long-term intraocular pressure control (Chen et al., 2006). In 
this study, Masson trichrome and ǃ-smooth muscle actin immunocytochemistry established 
reduction of myofibroblast population in the eye having bioactive matrix implant compared 
to control. The authors concluded that the collagen matrix may simulate a more 
physiological structure for tissue regrowth (Chen et al., 2006; Hsu et al., 2000). Scleral buckle 
composed of biodegradable collagen-glycosaminoglycan copolymer had been reported to be 
safe and effective in a rabbit model (Wu et al., 2008). Similar results have been demonstrated 
with modified porous poly(lactide-co-glycolide) scaffold as well (Lee et al., 2003). These 
findings provide insight into cellular behaviors and assist in the understanding of 
conjunctival tissue bioengineering. 
2.1.2 Conjunctival tissue substitutes 
2.1.2.1 Autologous mucosal transplantation 
Other therapeutic options for conjunctival tissue reconstitution include autologous tissue 
grafts and bioengineered conjunctival substitutes. Similar to any epithelia, the conjunctival 
epithelium is in a dynamic self-renewal equilibrium. Epithelial cells with high mitotic 
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capacity are distributed predominantly in the bulbar and forniceal conjunctiva in humans 
(Pellegrini et al., 1999; Tsubota et al., 2002). In autologous conjunctival autografts, e.g. for 
pterygium excision, the conjunctival autograft typically successfully replenishes the donor 
bed. However, severe tissue deficiency necessitates transplantation of other mucosal tissues. 
Other mucosal tissues having structure analogous to the conjunctiva, i.e. nonkeratinized 
stratified squamous epithelium with goblet cells, include nasal, esophageal, vaginal, and 
tracheal mucosa. Gibson and colleagues (1986) demonstrated the feasibility of transplanting 
oral epithelium onto the ocular surface in a rabbit model. In a case report, oral mucosa was 
used in combination with a modified Gunderson conjunctival flap to treat ocular surface 
burn injury (Cheng & Chang, 2006). In a series of patients with severe bilateral mucus 
deficiency syndrome after severe lye, acid, or heat burns, radiation, or systemic mucosal 
disease, autologous nasal mucosal grafts from the nasal conchae were transplanted to cover 
the ocular surface (Naumann et al., 1986). Symptomatic and visual improvements were 
reported. Long-term follow-up, using impression cytology and hematoxylin and eosin and 
periodic acid-Schiff staining of biopsied tissue, demonstrated that functional goblet cells 
persisted in autologous nasal mucosa for up to 10 years after transplantation (Wenkel et al., 
2000). Another study also reported similarly promising outcomes for patients with cicatricial 
ocular surface secondary to lye injury (Kim et al., 2010). 
2.1.2.2 Cultivated bioengineered tissues 
Currently, a variety of substrates are readily available for cultivation of conjunctival tissue, 
e.g. murine-derived 3T3 fibroblast feeder layer, human amniotic feeder layer, and serum-
free media. Irradiated 3T3 murine feeder cells are widely utilized in a number of cell culture 
systems because these immortalized 3T3 cells secrete growth factors to support cellular 
proliferation (Todaro & Green, 1963). Although the murine-derived feeder layers provide 
satisfactory support for tissue growth and maintenance, the tissue is unsuitable for human 
use because of several considerations. The xenoantigenic nonhuman sialic acid Neu5Gc 
produced by the human embryonic stem cells using this culture system may trigger cell 
killing in vivo if exposed to human serum containing circulating antibodies specific for 
Neu5Gc (Martin et al., 2005; Rheinwald 1980). Other concerns include transmission of 
murine diseases or contamination with virus or prion agents (Boneva et al., 2001; Ramarli et 
al., 1995).  
Consequently, alternatives are being explored. The human amniotic feeder layer, derived 
from human placentas, has been found to promote clonal growth of human limbal epithelial 
progenitors (Chen et al., 2007; Tanioka et al., 2006)). Such bioengineered tissues would be 
suitable candidates for replacement of native conjunctival tissue as the human amniotic 
membrane is a stable and elastic substratum that can be integrated into the ocular surface. 
The anti-inflammatory properties of human amniotic membrane would be especially 
advantageous in the case of inflammatory cicatricial changes, as any trauma to the recipient 
bed would reactivate or incite the inflammatory cascade that may inflict further injury to 
both the host and the graft. Other substrates include ultrathin poly(ǃ-caprolactone) 
membrane, silicone, and others (Ang et al., 2006; Selvam et al., 2006; Yoon et al., 2007). To 
minimize the biohazard of using xenobiotic materials, serum-free media are being 
investigated as well. One study demonstrated good epithelization following transplantation 
of serum-free autologous cultivated conjunctival epithelium on human amniotic membrane 
in pterygium excision (Ang et al., 2005). Tissue cultivation will be discussed in detail below. 
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2.2 Corneal epithelium reconstitution 
In humans, the known organs that demonstrate immunologic privilege are the eyes, brain, 
testicles, placenta, and fetus. The anterior chamber immunologic privilege and avascularity 
of the cornea significantly contribute to the high success rate of corneal allografts, e.g. 
penetrating keratoplasty, which can be performed without HLA-typing (Nguyen et al., 2007, 
2008, 2010). However, the risks of allogeneic graft rejection increase significantly in patients 
with severe ocular surface disorders or limbal stem cell deficiency. In severe cases, 
management of corneal blindness involves treatment of the ocular surface disorder, 
restoration of limbal stem cells, development of corneal tissue equivalents, or use of a 
keratoprosthesis. 
2.2.1 Human amniotic membrane transplantation 
Now widely employed in burn management and ophthalmology, the human amniotic 
membrane found its first applications as surgical dressing and tissue graft in dermal burns 
and as a strategy to impede tissue adhesion in mucosal injuries (Davis, 1910; Stern, 1913). 
Subsequently, its utility was expanded to reconstruction of the oral cavity, bladder, and 
vagina, as well as tympanoplasty and arthroplasty. De Rotth (1940) first reported the 
suitability of amniotic membrane in ocular surface reconstruction where he applied the 
amniochorion to repair symblepharon. A suboptimal surgical outcome was observed 
because the chorion component can incite inflammation and scarring. The amniotic 
membrane enjoyed limited use until the 1990s when its properties were better understood 
and its ophthalmic applications became widely adopted.  
In humans, the amniotic membrane, which lines the inner surface of the placenta, is 
composed of a basement membrane and a subjacent stromal matrix devoid of vascular and 
lymphatic vessels, as well as nerve fibers. It has many unique features, including 
suppression of inflammation and promotion of tissue healing. Its basement membrane 
assists in induction of adhesion and migration of epithelial cells for wound healing (Azuara-
Blanco et al., 1999; Dua et al., 2004; John et al., 2002; Kim & Tseng 1995; Shimazaki et al., 
1998). Modulation of the inflammatory cascade is realized by suppression of interleukin 
alpha and interleukin 1 beta in epithelial cells (Solomon et al., 2001). Release of growth 
factors such as epidermal growth factor, keratinocyte growth factor, or basic fibroblast 
growth factor (Koizumi et al., 2000) and inhibition of proteinase activity (Kim et al., 2000) 
promote tissue survival. The amniotic membrane also effectuates reduction of scar tissue 
formation by reducing polymorphonuclear infiltration (Park & Tseng, 2000) and 
suppressing the TGF-ǃ signaling system and myofibroblast differentiation of normal 
fibroblasts (Lee et al., 2000; Tseng, 1999). 
The available literature supports its use as an epithelial surrogate after excision of large 
ocular surface neoplasias (Espana et al., 2000; Gündüz et al., 2006; Tomita et al., 2006), 
reconstruction of conjunctival ocular surface (Solomon et al., 2003; Zhou et al., 2004; 
Oberhansli et al., 2005; Tseng et al., 2005), excision of pterygia (Ang et al., 2007; Nakamura et 
al., 2006), severe or refractory neurotrophic corneal ulcers (Chen et al., 2000; Ivekovic et al., 
2002; Khokhar et al., 2005), bacterial keratitis (Barequet et al., 2008), and symptomatic 
alleviation following acute ocular burns (Tamhane et al., 2005). A prospective 
noncomparative interventional case series study reported that nonpreserved human 
amniotic membrane appears useful for ocular surface reconstruction following excision of 
extensive ocular surface neoplasia, such as squamous cell carcinoma, malignant melanoma 
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and conjunctival-orbital lymphangioma (Gündüz et al., 2006). No immune graft rejection 
was encountered. For pterygium excision, complete epithelialization, early resolution of 
ocular inflammation, and no recurrence of pterygium had been reported following 
orthotopic transplantation of sterilized, freeze-dried amniotic membrane, over a follow-up 
period of 14 months (Nakamura et al., 2006). Caution is advised, however, in using amniotic 
membrane transplant for primary pterygium excision in patients with sufficiently 
recruitable conjunctiva. Randomized prospective studies comparing conjunctival autograft 
versus amniotic membrane transplant for pterygium showed a higher recurrence rate in the 
amniotic membrane transplant group (Essez et al., 2004; Luanratanakorn et al., 2006; 
Tananuvat & Martin, 2004). A recent study (Baraquet et al., 2008) demonstrated the use of 
human amniotic membrane in an animal model to assist in the healing of bacterial keratitis. 
In this rat model of Staphylococcus aureus keratitis, histopathologic examination revealed 
the least corneal haze and neovascularization in the cefazolin/amniotic membrane 
combination group, compared to the normal saline and amniotic membrane, and cefazolin 
without amniotic membrane transplantation groups.  
Complete ocular surface coverage using amniotic membrane was performed in patients 
with severe acute chemical and thermal burns to protect and promote conjunctival 
regeneration and to prevent complications of burns, such as symblepharon formation and 
corneal melt (Joseph et al., 1991). However, Joseph and colleagues did not observe a positive 
association between amniotic membrane transplantation and overall success rate of ocular 
surface restoration or preservation of ocular integrity in patients with severe acute burns, 
whether used alone or in conjunction with other surgical procedures. Using laser scanning 
in vivo confocal microscopy, Nubile et al (2001) discovered two different mechanisms of 
adhesion: when the amniotic membrane behaved as a patch, instead of as a graft, the 
epithelial cells migrated under the membrane, culminating in membrane disintegration; 
when the amniotic membrane acted as a graft, it became the basement membrane matrix, 
integrating with the superficial corneal stroma and allowing epithelial cell migration and 
proliferation (Nubile et al., 2001; Resch et al., 2006). This behavior potentially explains the 
poor outcome observed by Joseph et al (1991). Accordingly, care should be taken during 
transplantation to allow the membrane to be a graft, thus promoting epithelial migration 
and proliferation. Zhou et al (2004) noted that severity of the symblepharon, severity of 
decrease in lacrimal function, and a decreased amount of remaining healthy conjunctiva are 
poor prognostic factors for long-term outcomes of amniotic membrane transplantation for 
conjunctival surface reconstruction. A higher rate of failure was associated with 
preoperative use of topical steroid in patients receiving amniotic membrane transplantation 
for persistent epithelial defect and conjunctival repair (Saw et al., 2007). However, the 
preoperative use of steroids may simply be an indication of the severity of the disease.  
Traditionally, sutures are used to anchor the amniotic membrane to the ocular surface; 
however, there is a recent shift toward bioadhesive transfixation instead. There are a 
number of motivations for this shift: suture fixation requires a greater amount of surgical 
expertise and dexterity; sutures can cause corneal irritation and scarring; membrane 
shrinkage can result in graft loss; and sutures need to be extricated. For conjunctival 
autograft following pterygium excision, the biocompatibility, safety, and efficacy of fibrin 
bioadhesives was substantiated in a prospective randomized, interventional case series (Uy 
et al., 2005). In a rabbit model, Szurman et al (2006) demonstrated that fibrin glue provided a 
better surgical outcome than sutures for amniotic membrane transplantation. In the 
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bioadhesive group, histology revealed a smooth fibrin layer at the graft-host interface and a 
continuous, stratified layer of cytokeratin-3 expressing corneal epithelial cells on the 
membrane surface. The authors found that suture fixation tends to promote membrane 
contraction, raised membrane edges, and epithelial ingrowth into the submembrane space 
(Szurman et al., 2006). These findings were essentially corroborated in another study 
(Sekiyama et al., 2007). The fibrin bioadhesive biodegrades within 2 weeks, whereas the 
amniotic membrane persists for at least 12 weeks, providing sufficient time for 
epithelialization (Sekiyama et al., 2007). Sutureless transplantation with fibrin glue or 
ProKera™ is reportedly a safe and easy method that avoids complications related to sutures 
and shortens the time of surgery (Kheirkhah et al., 2006).  
2.2.1.1 Disadvantages of human amniotic membrane 
Amniotic membrane only provides a supportive substratum for epithelial stem cells to 
proliferate and migrate to restore the ocular surface. Thus, transplantation of the amniotic 
membrane without cultivated epithelial cells for true limbal stem cell deficiency may not be 
curative. Without the limbal stem cells and corneal epithelial cells, the cornea may not 
maintain avascularity and clarity because of secondary conjunctivalization and 
neovascularization of the cornea. In a retrospective case study, Maharajan et al (2007) 
reported the correlation between a higher success rate of ocular surface reconstruction using 
amniotic membrane transplantation and the availability of stem cells.  
There are some minor disadvantages of amniotic membrane transplantation. As already 
noted, suture fixation of amniotic membrane requires surgical dexterity to manipulate the 
membrane on the ocular surface. As a substrate for stem cell expansion, the surface with 
stem cells is transfixed face-up on the corneal surface. This position has some theoretical 
drawbacks: delayed migration of epithelial cells to the corneal surface before cellular 
repopulation, attrition of epithelial cells from exposure in patients with severe dry eye 
syndrome or ocular surface disorders, or mechanical displacement of the tissue. Another 
disadvantage is the association with corneal calcific opacification. In a large series of 
amniotic membrane transplantation for persistent epithelial defect, partial limbal stem cell 
deficiency and conjunctival reconstruction, Anderson and colleagues (2003) reported a 
significant (12.8%) rate of corneal calcification, occurring 3-17 weeks postoperatively. Risk 
factors were preoperative corneal calcification in either eye and postoperative use of 
phosphate-containing eye drops. A more recent study suggests that the use of phosphate-
buffered eye drops, commonly found in artificial tear or topical corticosteroid formulations, 
favors the formation of insoluble crystalline calcium phosphate hydroxyapatite deposits in 
the stroma in the presence of epithelial keratopathy (Bernauer et al., 2006). Studies using an 
animal model confirmed these findings as well (Schrage et al., 2010). The authors 
discouraged the use of phosphate-buffered eye drops as excessive use of such eye drops 
may cause corneal calcification, which may necessitate corneal graft surgery for subsequent 
visual rehabilitation. 
2.2.2 Epithelial cell transplantation 
Treatment of limbal stem cell deficiency includes transplantation of cultivated limbal stem 
cells. The unique properties of amniotic membrane make it an attractive candidate as a 
substratum for stem cell expansion. Tsubota and colleagues (1996) were among the first to 
introduce the combined transplantation of allograft limbal tissue and amniotic membrane in 
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patients with ocular cicatricial pemphigoid, where a short-term success rate of 86% was 
observed. Koizumi et al (2000) reported successful transplantation of cultivated corneal 
epithelium using acellular amniotic membrane as a substrate for ex vivo expansion of the 
epithelial cells. Nakamura et al (2004, 2006) proposed the application of sterilized, freeze-
dried amniotic membrane as a substrate for cultivating autologous corneal epithelial cells 
for ocular surface reconstruction. In a rabbit model, the authors reported no significant 
difference between freeze-dried and cryopreserved amniotic membrane. Corneal epithelium 
cultivated well and reepithelialization of the grafted cornea was demonstrated 
postoperatively (Nakamura et al., 2004, 2006). 
The conventional cultivation methods for mucosal epithelial tissues involve the use of 
xenobiotic materials such as fetal bovine serum (FBS) and murine-derived 3T3 feeder cells. 
Given the risks of zoonotic infection and xenoantigenic materials as discussed above, FBS-
free culture systems have been developed, but these have reduced efficacy for cell 
propagation. Ang et al (2006) introduced the use of human serum for in vivo and ex vivo 
expansion of human conjunctival epithelial cells on amniotic membranes. Cultivated 
epithelial cells on amniotic membrane substrates using autologous serum showed complete 
corneal epithelialization, retained corneal clarity, and improved visual acuity in patients 
with severe limbal stem cell deficiency (Nakamura et al., 2006). Autologous serum 
expansion and FBS expansion appeared to have comparable proliferative capacities with 
equivalent morphologies (Nakamura et al., 2006). Autologous serum had also been used to 
cultivate oral epithelial cells for patients with severe ocular surface disease with promising 
outcomes (Ang et al., 2006).  
Murine 3T3 feeder cells are typically used in these cultivation systems to maintain stemness 
of the stem cells. However, these xenobiotic feeders cannot be used for transplantation in 
humans. Accordingly, other culture systems, such as human amniotic epithelial cells, 
human embryonic fibroblasts or feeder cell-free, are being investigated for feasibility as the 
feeder cells. Chen and colleagues (2007) compared murine 3T3 cells and human amniotic 
epithelial cells, and found that, although murine 3T3 feeder cells demonstrated faster initial 
proliferative capacity, human amniotic epithelial feeder cells retained evidence suggestive of 
undifferentiated state for more generations. Lai et al. (2007) similarly concluded that human 
amniotic epithelial cells are suitable for cultivation of mouse embryonic stem cells, 
compared to mouse embryonic fibroblast feeder cells. Under both FBS-supplemented and 
serum-free conditions, human embryonic fibroblast feeder cells was found to support 
expansion of human limbal epithelial cells as well as 3T3 feeder cells (Notara et al., 2007). A 
feeder cell-free system had been introduced by Yokoo et al. in 2008. Of note, the authors 
found that, compared to conventional medium containing 10% FBS cocultured with 3T3 
fibroblast feeder cells, cells grown in serum-, feeder cell- and bovine pituitary extract (BPE)-
free culture medium demonstrated higher colony forming ability, equivalent proliferative 
capacity, and similar morphology. Two weeks after transplantation onto rabbit corneas, 
these cells showed histologic findings suggestive of normal corneal epithelium (Yokoo et al., 
2008). These autologous cultivation or serum- feeder cell- and BPE-free systems would 
theoretically reduce the risk of allograft rejection and transmission of xenobiotic infectious 
agents, and the need for long-term corticosteroid and immunosuppressive therapy may be 
obviated. Adoption of a standardized protocol to ensure availability of tissues with 
consistent constituents and consistent clinical outcomes would be desirable (Hopkinson et 
al., 2006). 
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2.2.3 Other substrates for epithelial cell cultivation 
Alternative materials are being investigated. Rama et al (2001) investigated the application 
of a fibrin substrate for cultivating autologous limbal stem cells. Good epithelization and 
regression of inflammation and vascularization were reported following transplantation 
onto corneas damaged by total limbal stem cell deficiency (Pellegrini et al., 1999; Rama et al., 
2001). These findings were corroborated by another group (Han et al., 2002). A more recent 
study comparing fibrin bioadhesive substrate and amniotic membrane for cultivation of 
corneal epithelial sheets showed that both had similar levels of colony-forming progenitor 
cells, while more differentiation was observed in the fibrin group (Higa et al., 2007). A 
thermoresponsive surface, which allows easy harvest of intact transplantable corneal 
epithelial cell sheets from ex vivo expansion of limbal stem cells, has been developed 
(Nishida et al., 2004). Without transplantation of the substratum, e.g. amniotic membrane, 
theoretically, this epithelial sheet will rapidly repopulate the corneal surface, without the 
time delay for migration. Using this technique, Nishida et al (2004) performed ex vivo 
fabrication of autologous oral mucosal tissue and transplantation on a small group of four 
patients with bilateral total corneal stem cell deficiencies with reasonable success. Lai et al 
(2007) also demonstrated successful transplantation of bioengineered human corneal 
endothelial cell monolayer sheet grafts, cultivated on the thermoresponsive surface then 
attached to gelatin hydrogel discs, into denuded rabbit corneas. Restoration of corneal 
clarity was observed, compared to controls.  
An innovative approach to cultivating cells on contact lens has recently been introduced (Di 
Girolamo et al., 2007). It was found that successful explant cultures could be made using 
either superior forniceal conjunctiva or superior limbal epithelial biopsies placed on a 
siloxane-hydrogel extended wear contact lens. These lenses were subsequently inserted onto 
the eyes of three patients with limbal stem cell deficiency. The patients were found to have a 
stable transparent corneal epithelium with no recurrence of conjunctivalization or corneal 
vascularization along with improvements in both best-corrected visual acuity and symptom 
scores. It is theorized that the close proximity between the therapeutic contact lens and the 
ocular surface facilitates cell migration from their artificial substratum to replenish the 
damaged ocular surface. Di Girolamo et al also postulated that the diffusion of secretory 
factors from the contact lens niche would promote corneal wound healing, inhibit 
angiogenesis, and rescue or activate any remaining limbal stem cells. Research is now being 
conducted to create a plasma polymer surface that can coat CL surfaces that would not only 
allow for appropriate attachment and growth of the epithelial cells but also transfer of the 
cultured cells onto the denuded corneal surface once inserted (Deshpande et al., 2010). This 
technology is similar to that being used in patients with extensive burn injuries and chronic 
nonhealing diabetic ulcers for transfer of autologous keratinocytes (Moustafa et al., 2004, 
2007; Zhu et al., 2005). Both rabbit and human corneal cells were able to attach and 
proliferate well on acrylic acid-coated contact lens surfaces, and there could be reliable 
transfer of epithelial cells to rabbit corneas (Deshpande et al., 2010). Other substrates for ex 
vivo cell expansion being investigated are composite membranes of alginate polymeric 
membrane coated with chitosan, NaOH-surface-modified poly(epsilon-caprolactone), three-
dimensional collagen-proteoglycan-based scaffolds, and human anterior lens capsule (Ang 
et al., 2006; Galal et al., 2007; Lai et al., 2007; Ma et al., 2007; Oztürk et al., 2006; Torbet et al., 
2007). Though studies have not yet been performed in humans, these results are indeed 
exciting in the realm of corneal stem cell therapy.  
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2.2.4 Autologous non-ocular tissues 
As discussed in the conjunctival section, when available, transplantation of autologous 
tissues is the treatment of choice to obviate the risks of allograft rejections despite the 
presence of the anterior chamber immunologic privilege. In cases of bilateral severe limbal 
stem cell deficiency, oral mucosal transplantation is an adequate alternative. Kinoshita and 
Nakamura proposed a two-step process for patients at increased risks for allograft rejection 
or patients having low tolerance for immunosuppressive therapies. Here, the autologous 
oral mucosal epithelial progenitor cells undergo ex vivo expansion prior to transplantation 
(Kinoshita & Nakamura, 2004). Ex vivo expansion of a carrier-free sheet is more beneficial 
than a direct transplantation of an autologous buccal mucosal graft because the latter 
typically contain opaque subepithelial fibrous tissue. A long-term study reported good 
epithelial coverage, regression or stabilization of corneal neovascularization, and improved 
visual acuity in a cohort of patients with severe ocular surface disorder (Inatomi et al., 2006; 
Nakamura et al., 2010). The main mechanisms of graft failure were loss of transplanted 
cultivated oral epithelial cells, leading to persistent epithelial defect, followed by invasion of 
neighboring conjunctival epithelial cells, infiltration of inflammatory cells, and 
neovascularization. And as expected, good graft survival, intact ocular surface integrity, and 
no inflammatory cell infiltration were observed in successful cases, (Nakamura et al., 2007). 
Another study also showed good results using human buccal mucosa cultivated on 
thermoresponsive surface with mitomycin-treated 3T3 feeder cells for patients with chronic 
conjunctival inflammation and limbal stem cell depletion (Nishida et al., 2004). Ex vivo 
expansion of embryonic stem cells or bone marrow-derived mesenchymal stem cells have 
been investigated with promising preliminary results (Homma et al., 2004; Ma et al., 2006; 
Oh et al., 2008). 
The advantages of these autologous tissues are a significant reduction of xenobiotic 
materials in the transplant, a decreased risk of infection, a minimized risk of allograft 
immunologic rejection, and a reduced need for immunosuppressive therapy. However, 
some authors still used the 3T3 murine feeder cells. Also, it would be intriguing to look at 
long-term restoration of corneal avascularity and clarity as these tissues are not corneal 
epithelium and do not possess innate limbal stem cells. 
2.2.5 Corneal tissue substitutes 
Severe ocular surface diseases not only affect the epithelium but also involve the corneal 
stroma as well. Thus, reconstitution of the ocular surface may provide symptomatic relief 
but not visual rehabilitation. Tissue bioengineering is required to regenerate corneal tissue 
equivalents that integrate into the host and restore vision. A number of substrates have been 
proposed as three-dimensional growth scaffolds for ocular tissues: irradiated acellular non-
human cornea disc (Zhang et al., 2007), fish scale-derived scaffold (Lin et al., 2010), collagen-
copolymer extracellular matrix (Li et al., 2003; Liu et al., 2006), silk film biomaterials 
(Lawrence 2008), and electrospun chitosan-graft-poly (ǃ-caprolactone)/poly (ǃ-
caprolactone) nanofibrous scaffolds for retinal progenitor cells (Chen et al., 2011). 
Since corneal stroma is composed of lamella of collagen fibrils, many investigators 
developed collagen-surface modified scaffolds to promote host tissue integration, repair and 
regeneration. Of note, Myung and colleagues (2007, 2008) used photolithography to 
construct a three dimensional collagen type I - poly(ethylene glycol)/poly(acrylic acid) "core 
and skirt" corneal prosthesis, which can support surface reepithelization and stromal 
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integration. In a rabbit model, the authors observed that corneal epithelium forms a 
confluent layer on the scaffold. The surface modification of collagen also assisted in the 
integration of the seeded corneal fibroblasts into the hydrogel skirt. Li et al (2003) performed 
lamellar keratoplasty using collagen-copolymer extracellular matrix scaffold in pigs. The 
authors reported increased procollagen synthesis and nerve regeneration, compared to 
control. Similar findings were reported by Liu et al (2006) using corneal substitutes made of 
cross-linked porcine type I collagen and water-soluble carbodiimides, in rabbit and minipig 
models. Using recombinant human collagens cross-linked with carbodiimide and 
hydroxysuccinimide, Merrett et al (2008) constructed bioengineered corneal equivalents for 
transplantation into minipigs. These synthetic corneal implants were found to be optically 
clear, with good epithelial coverage. Importantly, the authors also demonstrated 
repopulation of the synthetic stroma with host corneal stromal cells, as well as reinnervation 
with similar nerve density compared to allograft.  
3. Ocular surface prosthetic devices 
As discussed above, contact lenses are being investigated as a stem cell reservoir and 
delivery vehicle. Therapeutic applications of contact lenses extend to other uses as well, for 
symptomatic alleviation of aberrant ocular surface and drug delivery. Many individuals 
suffer severe eye discomfort and pain that is unresponsive to the mainstay treatment 
options. In these patients, the ocular surface can be improved by an ocular surface prosthetic 
device - not for limbal stem cell delivery but to create a microenvironment that supports the 
corneal surface, i.e. the Prosthetic Replacement of the Ocular Surface Ecosystem or PROSE, 
developed by Perry Rosenthal. The device itself is a fluid-ventilated, gas-permeable polymer 
with optic and haptic portions situated over the sclera that are linked to a transitional zone 
that suspends the lens over the cornea without contact. The unique design of this prosthesis 
provides a constant aqueous layer over the cornea surface, which contributes to healing of 
the corneal tissue and subsequent relief of symptoms (Rosenthal et al., 2000; Shepard et al., 
2009)). Studies have demonstrated corneal healing as soon as 6 hours after device placement 
(Takahide et al., 2007). Stason and colleagues (2010) reported improved visual acuity and 
visual function in a significant number of these patients. Better quality of life has been 
reported as well (Romero-Rangel et al., 2000).  
The most common route of drug delivery for the ocular surface is topical. This modality has 
some limitations, however, including rapid clearance from the ocular surface, short duration 
of therapeutic dosage, and systemic absorption (Bourlais et al., 1998; Ciolino et al., 2009; 
Ghate et al., 2008; Gulsen et al., 2004; Patton et al., 1978; Saettone et al., 2002). Accordingly, 
the use of contact lenses as drug delivery vehicles has been investigated. Sedlavek (1965) in 
Czechoslovakia first studied the use of soft contact lenses for drug delivery; since then many 
different drugs and technologies have been successfully tried using this technique 
(Sedlavek, 1965). The optimal design for a contact lens drug delivery system is one that 
allows for zero-order release kinetics, along with being comfortable and biocompatible 
(Ciolino et al., 2009). With these criteria in mind, the soft hydrogel lenses were the first 
lenses to be used in this capacity. The hydrogel lenses have high water content and large 
intermolecular pores, which allow them to absorb water soluble drugs and release them 
with a large initial pulse and then gradually thereafter (Jain, 1988). To maintain first-order 
kinetics, the hydrogel lens requires regular instillation of drops at intervals of 2-4 hours or 
reapplication of a soaked lens (Jain & Batra, 1970). This approach is suboptimal as drug 
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uptake and release kinetics are dependent on the equilibrium solubility of the drug present 
in the lens matrix (which is small for most of the hydrophobic drugs [Gulsen et al., 2004]), 
the inconvenience of frequent dosing, and the waste of drug remaining in the soaking 
solution.  
Efforts to overcome these limitations focus on lens designs that allow for a sustained release 
of therapeutic dosage. One idea involves the use of nanoparticles in which the ophthalmic 
drug could be encapsulated and then dispersed in the lens material (Gulsen et al., 2004). 
These so called “drug-laden hydrogels” were found to release therapeutic levels of drugs for 
a few days with the ability to manipulate drug delivery rates by varying the load of 
nanoparticles in the gel (Gulsen et al., 2004). This discovery allowed for lenses that could 
release drugs over extended periods of time and thus behaved in a zero order kinetic 
fashion. However, although this was exciting, the development of a sustained, long-term 
drug delivery system that functions under the physiological temperature, pH and salinity of 
the eye continues to be problematic (Ciolino et al., 2009). Most recently, research is being 
conducted on the development of prototype lenses that incorporate a dual polymer system 
such that there is a polymer film containing the drug compounds; the film is then coated 
with a transparent polymer that is used in contact lenses (Ciolino et al., 2009). The results 
with this new lens showed that there could be controlled release with zero-order kinetics for 
over 4 weeks (Ciolino et al., 2009). 
In addition to the soft hydrogel lens and their derivatives, collagen shields have also proven 
to be effective delivery modalities. The collagen shield contact lens is a therapeutic lens 
composed of non-cross linked porcine collagen with the capability of dissolving on the 
corneal surface over a period of around 12 hours (Phinney et al., 1988). Studies done using 
collagen shields soaked with gentamicin and vancomycin produced tear, cornea, and 
aqueous humor levels that were generally higher or comparable to those achieved through 
frequent drop administrations (Phinney et al., 1988). Further, collagen shields used for 
heparin delivery in postoperative rabbit eyes helped to prevent postoperative fibrin 
formation in eyes at risk for this complication (i.e. eyes requiring surgery for complications 
of proliferative diabetic retinopathy and glaucoma filtration surgery) (Murray et al., 1990). 
With time, as bioengineered materials continue to advance, so too will the quality of optimal 
delivery system contact lenses. Pharmacological contact lenses have the potential to 
revolutionize the current drug delivery modalities and conquer new ground in the long held 
battle of medication wastage and systemic absorption side effects.  
4. Restoration of lacrimal function 
Dry eye syndrome or dysfunctional tear syndrome is a chronic ailment, afflicting up to ten 
million people in the United States alone, and affecting women twice as often as men 
(Pflugfelder et al., 2000). As prevalent as it is, currently, there is only one medication 
(cyclosporine ophthalmic emulsion, 0.05%) approved by the Food and Drug Administration 
for decreased tear production due to ocular inflammation (Barber et al., 2005; Pflugfelder, 
2004). Dry eye syndrome tends to coexist with ocular surface disorder. Importantly, poor 
lacrimal function correlates with poor surgical outcomes in ocular surface reconstructions, 
especially stem cell transplantation (Nguyen et al., 2008; Shimazaki et al., 2000, 2007). 
Temporary remedies, such as artificial tears, hydroxypropyl cellulose ophthalmic insert, 
punctal plugs, or moisture-chamber spectacles often provide only marginal relief and may 
interfere with the patient’s quality of life. A long-term solution is the construction of an 
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implantable lacrimal microbiosystem, which would house a colony of monolayer lacrimal 
acinar cells and produce tear fluid (Selvam et al., 2006, 2007, 2008). 
4.1 Artificial lacrimal gland 
The parenchyma of the lacrimal gland consists of specialized epithelia: ductal cells and 
acinar cells. The acinar cells form an acinus structure whose wall is composed of a polarized 
monolayer of cells. These lacrimal acinar epithelial cells are responsible for production and 
release of tear proteins such as lactoferrin, growth factors, secretory immunoglobulins, and 
lysosomal hydrolases into nascent tear fluid (Fullard, 1994). Their apices point toward a 
central lumen into which tear fluid is secreted. Many acini form a lobule. The ductal cells 
line the intralobular and interlobular ducts, bringing tear fluid into the eye. An implantable 
lacrimal microbiosystem would approximate the structure and function of the lacrimal 
gland. Figure 2 depicts a schematic artificial lacrimal gland using a dead-end tube concept.  
 
 
Fig. 2. Schematic of an artificial lacrimal gland where lacrimal acinar cells are seeded in a 
three-dimensional housing, allowing nutritional support from the environment and egress 
of tear fluid from the artificial gland. 
Development of such devices faces many challenges. As with any implantable devices, a 
lacrimal microbiosystem must have a biologically compatible encapsulation to prevent 
rejection or toxicity to the host. However, the lacrimal microbiosystem encapsulation is 
much more intricate. Instead of a closed system, the enclosure must allow a dynamic bi-
directional flux of ions, fluid, nutrients, and materials between the device and the host, 
while downregulating reactive fibroblastic proliferation in the surrounding environment 
that may diminish material transfer. Tear production is regulated by a variety of control 
modalities, such as regenerated intrinsic neurostimulation, extrinsic pharmacologic 
induction, or electronic excitation. Device construction includes ex-vivo seeding and 
maturation of the lacrimal acinar cells into a three-dimensional bioengineered scaffold. 
Strategic placement of pluripotent stem cells may be necessary. The stem cell clusters within 
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the scaffold would repopulate the lacrimal acinar tissue, as needed. Precise stimuli for 
regeneration and terminal differentiation would be provided by extrinsic delivery or 
activation of previously implanted nanovesicles containing plasmids coding for growth 
factors, for example. As a stem cell device, safeguard mechanisms must be instituted to 
monitor and prevent autonomous unstructured proliferation and escape of the stem cells, 
i.e. tumorigenicity. 
Recent studies demonstrated monolayer growth of lacrimal acinar cells on Matrigel®, a 
biocompatible preparation rich in extracellular matrix molecules, i.e. laminin, collagen IV, 
heparin-sulfate proteoglycans, and growth factors (Selvam et al., 2006, 2007, 2008). 
Compared to other biocompatible polymeric materials, poly-L-lactic acid (PLLA)-Matrigel® 
substrate showed superior expression of monolayer acinar cell morphology. Active 
exocytosis vesicle profile was evident on electron microscopy, and maintenance of protein 
secretory functions was confirmed by ǃ-hexosaminidase catalytic activity assay. PLLA and 
PLGA copolymers have a wide range of applications: surgical sutures, scaffolds in bone 
augmentation and ligament restoration, osteoconductive materials in dental medicine, and 
components in vascular grafts, urethral stents, and nerve growth conduits. Growth of 
polarized lacrimal acinar cells on PLLA, which demonstrated the ability to maintain normal 
monolayer acinar cell morphology, secretory function, and EGF-dependent proliferation, 
suggests that PLLA may be a good candidate for the development of a tear secretory device. 
A dead-end tube construct using polyethersulfone has been reported (Li et al., 2006; Liu et 
al., 2009). After seeding the tube with cultured rat lacrimal acinar epithelial cells, the authors 
observed that a polyethersulfone dead-end tube may be suitable for attachment and 
proliferation of these cells, allowing its potential application as an artificial lacrimal gland. 
4.2 Tear film measurements 
Patients with ocular surface disorders typically have an underlying inflammatory process, 
such as ocular cicatricial pemphigoid, Stevens-Johnson syndrome, Sjögren syndrome, or 
post chemotherapy. The persistent inflammatory process and dysfunctional tear film lead to 
poor surgical outcomes. Good preoperative lacrimal function and a healthy conjunctival 
epithelium are important prognostic factors for limbal stem cell transplantation (Tsubota et 
al., 1999; Shimazaki et al., 2000). In fact, having a preoperative Schirmer’s test > 10 mm 
correlates to a higher success rate for ocular surface reconstruction. Accordingly, 
preoperative characterization of tear film is important for ocular surface reconstruction. 
Traditionally, tear production and quality are accessed using vital dye stain, tear break-up 
time, Schirmer's test, or the cotton-thread test. However, these tests have suboptimal 
repeatability, inter-class correlation, and correlation between the test results and patient 
symptom (Jordan & Baum, 1980; Lin et al 2005; Machado et al., 2009; Mainstone 1996; Nicols 
et al., 2004; Saleh et al., 2006; Savini et al., 2008; Schein et al., 1997; Yokoi & Komuro 2004). 
They are likely to also produce erroneous results by disrupting the natural tear film, 
affecting tear production, and modifying the tear film structure. Accordingly, recent efforts 
are directed toward non-invasive optical imaging techniques. 
Anterior segment optical coherence tomography (OCT) is a noninvasive technology using a 
laser to quantitatively measure the tear film and tear meniscus without ocular surface 
contact or fluorescein dye instillation (Huang et al., 1991, 2008; Ibrahim et al., 2010; Shen et 
al., 2009; Wang et al., 2006; Zhou et al., 2009). Tear film measurement using OCT showed 
good correlation with Schirmer's test and patient symptom score. Figure 3 portrays 
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application of anterior-segment OCT for measurement of lower tear meniscus height, depth, 
and cross-sectional area. OCT may also be used to measure the tear film or the upper tear 
meniscus. Other noninvasive technologies include slit-lamp equipped micrometer 
(Mainstone et al., 1996), slit-lamp photography (Kawai et al., 2007), and reflective 
meniscometry (Yokoi et al., 1999).  
 
 
Fig. 3. Lower tear meniscus measurement using anterior segment optical coherence 
tomography. (A) Anatomy of the lower tear meniscus; the inset illustrates the scan position. 
(B) and (C) Caliper measurement protocol. 
4. Conclusion 
The corneal epithelium, conjunctival epithelium, tear film and lacrimal system, and the 
eyelids constitute the functional ocular surface. Management strategies for severe ocular 
surface disorders involve treatment and prevention of recurrence of the causative condition, 
symptomatic alleviation, and reconstitution of the anatomic and physiologic ocular surface. 
Human amniotic membrane transplantation with or without epithelial graft is a versatile 
modality for various injuries to the ocular surface epithelia. Other options for reconstitution 
of the epithelia include suppression of cicatricial changes, autologous mucosal 
transplantation, or cultivated bioengineered tissues. Motivated by the risk of zoonotic 
disease transmission or xenobiotic immunogenicity, researchers worldwide are 
investigating serum-free feeder cell-free culture systems for ex vivo expansion of epithelial 
tissues for ocular surface applications. The results of these investigations are promising. 
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Normal lacrimal function is not only important for symptomatic alleviation and optical 
pursuits; it is also exceedingly essential for surgical outcomes. Preoperative tear film is an 
important prognostic indicator for ocular surface reconstruction. Strategies for tear film 
restoration include lubrication, moisture chamber, and artificial lacrimal glands.  
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